Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Feb 27, 2024; 16(2): 140-145
Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.140
Interleukins in liver disease treatment
Ming Yang, Chun-Ye Zhang
Ming Yang, Department of Surgery, University of Missouri, Columbia, MO 65212, United States
Chun-Ye Zhang, Bond Life Sciences Center, University of Missouri, Columbia, MO 65212, United States
Author contributions: Yang M and Zhang CY designed, collected data, wrote, revised, and finalized the manuscript, contributed equally, and shared the first authorship.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming Yang, DVM, PhD, Research Assistant Professor, Department of Surgery, University of Missouri, Room 2203, NextGen Precision Building, 1030 Hitt Street, Columbia, MO 65212, United States. yangmin@health.missouri.edu
Received: December 4, 2023
Peer-review started: December 4, 2023
First decision: December 17, 2023
Revised: December 22, 2023
Accepted: January 8, 2024
Article in press: January 8, 2024
Published online: February 27, 2024
Processing time: 85 Days and 11.2 Hours
Core Tip

Core Tip: Interleukins as a large group of cytokines play pleiotropic roles in liver homeostasis and disease by regulating both innate and adaptive immune responses. They can be divided into seven families, and all of them are involved in the pathogenesis and resolution of chronic liver diseases. Currently, interleukin-mediated therapies are applied in patients with hepatitis induced by alcohol or hepatitis virus infection.